Feeds:
Posts
Comments

Posts Tagged ‘hiv vaccine’

April 29, 2013

In the latest of a string of major setbacks in the search for an HIV vaccine, researchers have shuttered a trial after the experimental vaccine failed to both prevent HIV transmission and to reduce viral load in those who contracted the virus, the Los Angeles Times reports. The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), ordered all sites to cease immunizations after an independent review board ascertained that more people receiving the vaccine became infected with HIV than those receiving the placebo—although this difference was not statistically significant and may have been a result of chance.

Called HVTN 505, the Phase IIb study was conducted by the NIAID-supported HIV Vaccine Trials Network (HVTN). It began in 2009 and enrolled 2,504 men who have sex with men (MSM) and transgendered people who have sex with men in 21 sites in 19 U.S. cities. The vaccine built on the moderate success of the a vaccine called RV-144 that reduced infection rates among heterosexuals in Thailand by 30 percent, but which was shut down in 2009 because its protection rate was still not high enough. The vaccine was designed to induce an immune response against all three subtypes of the virus.

Among the 1,250 participants who received the experimental vaccine in the latest trial, 41 became HIV positive during the study, while among the 1,244 receiving the placebo, 30 participants contracted the virus. During the first 28 weeks of the study, 23 participants became infected with HIV, including 15 who received the vaccine and nine who received the placebo. The NIAID stated in a release that further analysis is needed to determine if the increased proportion of infections in the active agent group were a result of chance.

The vaccine also failed to reduce the viral load of those who became HIV positive during the trial.

In a release statement, NIAID asserted that it “remains committed to the pursuit of a highly effective, preventive HIV vaccine as part of a multifaceted HIV prevention research program.”

To read the AIDSMeds article CLICK HERE

To read the Los Angeles Times story, click here.

To read the NIAID release, click here.

Read Full Post »

The topic this Wednesday is the Cure or a Vaccine for HIV/AIDS.   What are some leading candidates?   What does a cure or vaccine mean?   What is being reported and how to read the reports.

If you have information on cures or vaccines, bring them to meeting to discuss .

I found two vaccines to discuss

Medical researchers in Spain say an experimental vaccine against HIV, the virus that causes AIDS, has produced a 90 percent immune response among a small group of healthy human test subjects. The promising results pave the way for further clinical trials on HIV-infected volunteers.

To read article CLICK HERE 

How the vaccine works:  CLICK HERE

Lost in translation; CLICK HERE

An experimental vaccine developed by a Johnson & Johnson unit and the U.S. military protected monkeys against an animal version of the AIDS virus, a study found.    Monkeys that got the vaccine were as much as 83 percent less likely than those that got a dummy shot to become infected with simian immunodeficiency virus.

To read full article CLICK HERE.

Read Full Post »

http://platform.twitter.com/widgets/hub.1324331373.html

A Groundbreaking HIV Vaccine Could Be on the Horizon

A unique and potentially landmark vaccine against the HIV virus has been shown to be safe and effective in animals. Now researchers have received the green light to test it in humans.

WEDNESDAY Dec. 21, 2011 — On Tuesday, the U.S. Food and Drug Administration (FDA) gave Canadian researchers approval to begin testing a potential HIV vaccine in humans beginning in January, according to HealthDay.

University of Western Ontario scientists, backed by the pharmaceutical company Sumagen, have already tested the vaccine in lab animals. These early tests demonstrated a strong immune response and no adverse effects.

The SAV001 vaccine works by using a dead HIV-1 virus that is non-pathogenic — meaning it’s genetically engineered to prevent spreading HIV to vaccine recipients — to trigger an immune response in patients, killing any cells that might become infected with HIV.

Though scientists have attempted to create HIV vaccines in the past, certain genes or proteins from the HIV virus were used instead of the whole virus. The researchers developing the SAV001 vaccine are the first to use this new approach.

Because this potential HIV vaccine uses the whole virus, it is similar to vaccines used for polio and the flu.

“When [researchers] came out with the polio vaccine, polio was eradicated in developed countries. I’d like to see that I can do that against the HIV infection,” says Chil-Yong Kang, MD, a virologist at the University of Western Ontario.

The Phase I trial — which will test the vaccine in 40 HIV-positive volunteers — is set to begin in January. If successful, further clinical trials will be performed to determine the vaccine’s effectiveness.

The Phase II trial will test about 600 HIV-negative people who are at high risk for the virus, and the

Phase III trial will test about 6,000 HIV-negative people who are at high risk for the virus.

To read full article CLICK HERE

 

Read Full Post »

New HIV Vaccine

HIV MVA-B Vaccine May Reduce Virus To ‘Minor Chronic

 Infection’

Spanish scientists in Madrid say a new vaccine could reduce HIV to a “minor chronic infection” like herpes.  

The researchers report that 90% of participants given the MVA-B vaccine showed an immune response to the virus and 85% kept the immunity a year later.

The success of this vaccine is based on the capability of human’s immune system to learn how to react over time against virus particles and infected cells.

MVA‐B is an attenuated virus, which has already been used in the past to eradicate smallpox, and also as a model in the research of many other vaccines.

Once injected, the vaccine teaches the volunteer’s immune system to track down and fight off the virus. 

This vaccine still needs  to pass Phase II and Phase III clinic trials, before it makes it into production.

Read full article here:  Link

 

Read Full Post »